+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia Pacific Veterinary Oncology Market By Animal Type, By Therapy, By Cancer Type, By Country, Industry Analysis and Forecast, 2020 - 2026

  • PDF Icon

    Report

  • 90 Pages
  • April 2020
  • Region: Asia Pacific
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5026331
The Asia Pacific Veterinary oncology Market is expected to witness market growth of 14.6% CAGR during the forecast period (2020-2026).

Cancers are among the most common diseases that affect dogs. Some of them arise naturally and exhibit certain parallels to human cancers in their physiology and histopathology. There is more, it is seen that there are many more analogies between these two species in the molecular pathways of cancer development. Human oncology is finding more and more effective approaches to diagnose an early illness that results directly in the increased life span of infected animals.

One of the most common trends of cancer treatment is the presence of circulating tumor cells (CTC) of patient blood. These cells are known to be responsible for the development of metastases in distant organs which results in patient death. It is also known that CTC is still present in the early stages of tumor growth in the bloodstream of patients. There is no evidence that the cause for the production of metastasis in dogs is similar, and that the CTC is still found in their bloodstream. Despite rigorous research, there is still no ideal way to separate cancer cells from the blood where they barely exist.

The growing prevalence of zoonotic and foodborne diseases worldwide has driven companies to establish successful testing solutions for both animals and pets. In fact, growth in the demand for veterinary diagnostics is supported by growing spending on animal healthcare and a favorable regulatory scenario for diagnostic approval. The growing use of in vitro diagnostic tests and advanced innovations like nanotechnology, fluorometric diagnosis, biosensors, wearables, and biomarkers has helped this market grow. Research centers and laboratories also report a surge in demand for in-house equipment and techniques for diagnosis.

Based on Animal Type, the market is segmented into Canine and Feline. Based on Therapy, the market is segmented into Chemotherapy, Radiology, Surgery, Immunotherapy and Others. Based on Cancer Type, the market is segmented into Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Karyopharm Therapeutics, Inc., Regeneus Ltd., Elanco Animal Health, Inc., Zoetis, Inc., Varian Medical Systems, Inc., PetCure Oncology, LLC (Accelitech, LLC), AB Science SA, Rhizen Pharmaceuticals S.A., and Nippon Zenyaku Kogyo Co., Ltd.

Scope of the Study

Market Segmentation:

By Animal Type
  • Canine and
  • Feline

By Therapy
  • Chemotherapy
  • Radiology
  • Surgery
  • Immunotherapy and
  • Others

By Cancer Type
  • Lymphoma
  • Mast Cell Cancer
  • Mammary & Squamous Cell Cancer and
  • Others

By Country
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Companies Profiled:
  • Boehringer Ingelheim International GmbH
  • Karyopharm Therapeutics, Inc.
  • Regeneus Ltd.
  • Elanco Animal Health, Inc.
  • Zoetis, Inc.
  • Varian Medical Systems, Inc.
  • PetCure Oncology, LLC (Accelitech, LLC)
  • AB Science SA
  • Rhizen Pharmaceuticals S.A.
  • Nippon Zenyaku Kogyo Co., Ltd.

Unique Offerings from the Publisher:
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Veterinary Oncology Market, by Animal Type
1.4.2 Asia Pacific Veterinary Oncology Market, by Therapy
1.4.3 Asia Pacific Veterinary Oncology Market, by Cancer Type
1.4.4 Asia Pacific Veterinary Oncology Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Mergers & Acquisitions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2015-2019)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2016, Sep - 2019, Nov) Leading Players
Chapter 4. Asia Pacific Veterinary Oncology Market by Animal Type
4.1 Asia Pacific Canine Market by Country
4.2 Asia Pacific Feline Market by Country
Chapter 5. Asia Pacific Veterinary Oncology Market by Therapy
5.1 Asia Pacific Chemotherapy Market by Country
5.2 Asia Pacific Radiology Market by Country
5.3 Asia Pacific Surgery Market by Country
5.4 Asia Pacific Immunotherapy Market by Country
5.5 Asia Pacific Other Therapy Market by Country
Chapter 6. Asia Pacific Veterinary Oncology Market by Cancer Type
6.1 Asia Pacific Lymphoma Market by Country
6.2 Asia Pacific Mast Cell Cancer Market by Country
6.3 Asia Pacific Mammary & Squamous Cell Cancer Market by Country
6.4 Asia Pacific Others Market by Country
Chapter 7. Asia Pacific Veterinary Oncology Market by Country
7.1 China Veterinary Oncology Market
7.1.1 China Veterinary Oncology Market by Animal Type
7.1.2 China Veterinary Oncology Market by Therapy
7.1.3 China Veterinary Oncology Market by Cancer Type
7.2 Japan Veterinary Oncology Market
7.2.1 Japan Veterinary Oncology Market by Animal Type
7.2.2 Japan Veterinary Oncology Market by Therapy
7.2.3 Japan Veterinary Oncology Market by Cancer Type
7.3 India Veterinary Oncology Market
7.3.1 India Veterinary Oncology Market by Animal Type
7.3.2 India Veterinary Oncology Market by Therapy
7.3.3 India Veterinary Oncology Market by Cancer Type
7.4 South Korea Veterinary Oncology Market
7.4.1 South Korea Veterinary Oncology Market by Animal Type
7.4.2 South Korea Veterinary Oncology Market by Therapy
7.4.3 South Korea Veterinary Oncology Market by Cancer Type
7.5 Singapore Veterinary Oncology Market
7.5.1 Singapore Veterinary Oncology Market by Animal Type
7.5.2 Singapore Veterinary Oncology Market by Therapy
7.5.3 Singapore Veterinary Oncology Market by Cancer Type
7.6 Malaysia Veterinary Oncology Market
7.6.1 Malaysia Veterinary Oncology Market by Animal Type
7.6.2 Malaysia Veterinary Oncology Market by Therapy
7.6.3 Malaysia Veterinary Oncology Market by Cancer Type
7.7 Rest of Asia Pacific Veterinary Oncology Market
7.7.1 Rest of Asia Pacific Veterinary Oncology Market by Animal Type
7.7.2 Rest of Asia Pacific Veterinary Oncology Market by Therapy
7.7.3 Rest of Asia Pacific Veterinary Oncology Market by Cancer Type
Chapter 8. Company Profiles
8.1 Boehringer Ingelheim International GmbH
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Karyopharm Therapeutics, Inc.
8.2.1 Company overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.3 Regeneus Ltd.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Research & Development Expense
8.4 Elanco Animal Health, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Acquisition and Mergers:
8.5 Zoetis, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.6 Varian Medical Systems, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Acquisition and Mergers:
8.6.5.2 Partnerships, Collaborations, and Agreements:
8.6.5.3 Product Launches and Product Expansions:
8.7 PetCure Oncology, LLC (Accelitech, LLC)
8.7.1 Company Overview
8.7.2 Recent strategies and developments:
8.7.2.1 Partnerships, Collaborations, and Agreements:
8.8 AB Science SA
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Research & Development Expense
8.9 Rhizen Pharmaceuticals S.A.
8.9.1 Company Overview
8.1 Nippon Zenyaku Kogyo Co., Ltd.
8.10.1 Company Overview

Companies Mentioned

  • Boehringer Ingelheim International GmbH
  • Karyopharm Therapeutics, Inc.
  • Regeneus Ltd.
  • Elanco Animal Health, Inc.
  • Zoetis, Inc.
  • Varian Medical Systems, Inc.
  • PetCure Oncology, LLC (Accelitech, LLC)
  • AB Science SA
  • Rhizen Pharmaceuticals S.A.
  • Nippon Zenyaku Kogyo Co., Ltd.

Methodology

Loading
LOADING...